News

Recent news about Panacea Venture and select portfolio companies

June 24, 2025

Revolutionizing the Canavan Disease Treatment Market

Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.

June 24, 2025

Revolutionizing the Canavan Disease Treatment Market

Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.

June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.

June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.

June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance  … Read more

June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance  … Read more

May 13, 2025

Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans

The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.

May 13, 2025

Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans

The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.

October 1, 2024

Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease

Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.

October 1, 2024

Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease

Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.